| Aug 6 |
TG Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call Transcript
|
| Aug 6 |
TG Therapeutics Stock Jumps As Surprise Profit Smashes Views By 157%
|
| Aug 6 |
TG Therapeutics secures $250M debt financing
|
| Aug 6 |
TG Therapeutics jumps after strong Q2 beat and guidance raise
|
| Aug 6 |
TG Therapeutics (TGTX) Surpasses Q2 Earnings and Revenue Estimates
|
| Aug 6 |
TG Therapeutics GAAP EPS of $0.04 beats by $0.09, revenue of $73.47M beats by $7.58M
|
| Aug 6 |
TG Therapeutics: Q2 Earnings Snapshot
|
| Aug 6 |
TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
|
| Aug 5 |
TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update
|
| Jul 30 |
TG Therapeutics, Inc.'s (NASDAQ:TGTX) recent 3.1% pullback adds to one-year year losses, institutional owners may take drastic measures
|
